Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026
I'm PortAI, I can summarize articles.
Tonix Pharmaceuticals announced updates on TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, aiming for FDA discussions in 2026. The antibody is designed for annual use to protect against Lyme disease during tick season. The company also revealed a securities purchase agreement with Point72 for $20 million to support product commercialization and development. TNXP shares rose 0.80% to $16.39 following the announcement.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments